Elevated Rate Pacing of Cardiac Amyloidosis

Recruiting now · Not applicable

Conditions studied: Cardiac Amyloidosis, Pacemaker

In brief

This study aims to better quantify the improvements in heart failure symptoms and exercise tolerance before and after the heart rate elevation in a cohort of 10 cardiac amyloidosis patients with preexisting pacemakers.

Key facts

Study ID

NCT07583823

Run by

University of Minnesota

People needed

10

Starts

2025-10-10

Expected to finish

2026-10-10

Last updated by the study team

2026-05-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults 18 and older
• Diagnosis of cardiac amyloidosis as indicated by the criteria set forth in guidelines such as in Kittleson et al: "2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee
• Implanted Cardiac Pacemaker (+/- Defibrillator)
• Pacemaker mode of AAI or DDD if in sinus rhythm, VVI acceptable if permanent atrial fibrillation
• Non-dilated left ventricle by echocardiography
• Ability to provide written consent
• English Speaking

You may not qualify if…

• Paced QRS duration of >150 ms (indicator for pacing mediated dyssynchrony)
• Dilated left ventricle

Where it is running

• University of Minnesota — Minneapolis, Minnesota, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.